|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Exelixis |
| Information provided by: | Exelixis |
| ClinicalTrials.gov Identifier: | NCT00350831 |
Purpose
The purpose of this study is to assess the safety and tolerability of the KIT inhibitor XL820 when given orally daily to adults with advanced solid tumors.
| Condition | Intervention | Phase |
|
Cancer |
Drug: XL820 |
Phase I |
| MedlinePlus related topics: | Cancer |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
| Official Title: | A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the KIT Inhibitor XL820 Administered Orally Daily to Subjects With Solid Tumors |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, New Jersey | |||||
| The Cancer Institute of New Jersey | |||||
| New Brunswick, New Jersey, United States, 08901 | |||||
| United States, Texas | |||||
| Cancer Therapy and Research Center | |||||
| San Antonio, Texas, United States, 78229 | |||||
| Exelixis |
More Information
| Study ID Numbers: | XL820-002 |
| First Received: | July 7, 2006 |
| Last Updated: | August 14, 2008 |
| ClinicalTrials.gov Identifier: | NCT00350831 |
| Health Authority: | United States: Food and Drug Administration |
|